OTC$PTN
Palatin Technologies Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Palatin Technologies reported results for the second quarter ended December 31, 2019.
Palatin Technologies reported a net loss of $5.2 million for the quarter ended December 31, 2019. The company's cash position was enhanced to $92 million as of December 31, 2019, and they are advancing their pipeline programs with two Phase 2 clinical studies starting in the first half of calendar year 2020.
- Vyleesi® FDA approval in June 2019 provided a safe and effective treatment option for premenopausal women with HSDD.
- Cash position was enhanced to $92 million at December 31, 2019.
- Two Phase 2 clinical studies are starting in the first half of calendar year 2020: a dry eye disease study and an ulcerative colitis trial.
- AMAG announced plans to divest Vyleesi® based on a change in strategy, not launch performance.
Headline financials
Revenue & EPS history
Palatin Technologies · Revenue · Quarterly
$20.6K
Forward guidance
Palatin is advancing discussions on Vyleesi collaborations for territories outside North America, China, and Korea, and anticipates executing multiple agreements during calendar year 2020. A Phase 2 clinical study for PL9643 in dry eye disease is expected to commence in Q1 2020, with data readout anticipated in Q4 2020. A Phase 2 proof-of-concept clinical study with an oral formulation of PL8177 in ulcerative colitis patients is anticipated to start mid-calendar year 2020, with data readout mid-calendar year 2021.
Tailwinds
- Advancing discussions on Vyleesi collaborations for territories outside North America, China, and Korea.
- Anticipates executing multiple agreements during calendar year 2020.
- Phase 2 clinical study for PL9643 in dry eye disease expected to commence in Q1 2020.
- Data readout anticipated in Q4 2020 for the dry eye disease study.
- Phase 2 proof-of-concept clinical study with PL8177 in ulcerative colitis patients anticipated to start mid-calendar year 2020.
Headwinds
- AMAG's planned divestiture of Vyleesi introduces uncertainty.
- Potential need to ensure the value of Vyleesi remains intact and continues to grow during the divestiture process.
- Dependence on AMAG to use commercially reasonable efforts to commercialize Vyleesi.
- Risk of AMAG materially breaching its obligation, potentially leading to termination of the license agreement.
- Need for the assignee of the Vyleesi license to expressly agree to be bound by the existing license agreement.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-2.4%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-2.5%
Avg return
30 days after
31%
20 / 64 earnings
Positive
+36.4%
Q3 2026
Best reaction
-27.1%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.2% | +29.2% | +18.2% | |
| Q1 2026 | +0.0% | +27.8% | +152.3% | |
| Q3 2026 | +36.4% | +9.1% | -9.1% | |
| Q3 2025 | +22.2% | +55.6% | +11.1% | |
| Q2 2025 | +7.1% | +4.0% | -20.2% | |
| Q1 2025 | -21.5% | -21.8% | -26.1% | |
| Q4 2024 | -8.3% | -1.1% | +39.3% | |
| Q3 2024 | -15.4% | -15.4% | -24.5% | |
| Q2 2024 | -27.1% | -21.7% | -62.8% | |
| Q1 2024 | -1.0% | -2.5% | +31.3% | |
| Q4 2023 | -8.5% | +19.7% | +13.3% | |
| Q3 2023 | -5.8% | -3.1% | -13.9% | |
| Q2 2023 | -8.8% | -2.2% | -18.0% | |
| Q1 2023 | -9.0% | -5.8% | -25.7% | |
| Q4 2022 | -19.5% | -27.7% | -43.6% | |
| Q3 2022 | -7.7% | -10.3% | -28.2% | |
| Q2 2022 | +5.0% | +0.0% | +2.5% | |
| Q1 2022 | -2.5% | -10.0% | +35.0% | |
| Q4 2021 | -6.4% | -8.5% | -12.8% | |
| Q3 2021 | +9.8% | +13.4% | +10.4% | |
| Q2 2021 | -19.5% | -23.9% | -33.6% | |
| Q1 2021 | +7.3% | +2.4% | +4.9% | |
| Q4 2020 | +0.0% | -4.2% | -20.8% | |
| Q3 2020 | -2.2% | -2.2% | +30.4% | |
| Q2 2020 | -14.1% | -18.3% | -39.4% | |
| Q1 2020 | -4.9% | -2.5% | -1.2% | |
| Q4 2019 | +7.1% | +3.0% | -16.2% | |
| Q3 2019 | +2.2% | +7.9% | -10.1% | |
| Q2 2019 | +2.7% | +6.8% | +36.5% | |
| Q1 2019 | -10.8% | -17.2% | -21.5% | |
| Q4 2018 | -3.8% | -2.9% | -14.3% | |
| Q3 2018 | -4.6% | -7.6% | -22.9% | |
| Q2 2018 | +5.6% | +7.8% | +6.7% | |
| Q1 2018 | +0.0% | +8.7% | +10.0% | |
| Q4 2017 | -6.1% | +0.0% | +15.2% | |
| Q3 2017 | -12.8% | -10.6% | -25.5% | |
| Q2 2017 | -6.8% | -11.4% | -22.7% | |
| Q1 2017 | -5.5% | -5.5% | +1.8% | |
| Q4 2016 | -1.8% | +16.1% | -3.6% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -7.7% | — | — | |
| Q4 2015 | -8.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +23.0% | — | — | |
| Q1 2015 | +4.0% | — | — | |
| Q4 2014 | -5.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | -7.0% | — | — | |
| Q1 2014 | +15.3% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q3 2013 | +1.6% | — | — | |
| Q2 2013 | -5.9% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2011 | +5.0% | — | — | |
| Q3 2012 | +5.0% | — | — | |
| Q2 2012 | -5.9% | — | — | |
| Q2 2011 | -5.9% | — | — | |
| Q1 2012 | -3.8% | — | — | |
| Q1 2011 | -3.8% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2010 | -9.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro